import Navbar from '@/components/Navbar';
import Footer from '@/components/Footer';
import { Link } from 'react-router-dom';
import { SEOHead } from '@/components/seo/SEOHead';
import { BreadcrumbNav } from '@/components/seo/BreadcrumbNav';
import { FAQSection } from '@/components/healthcare-research/FAQSection';
import { buildBreadcrumbSchema } from '@/lib/seo/schemas';
import { getStandaloneReportConfig } from '@/data/reportConversionConfig';
import { MarketIntelligenceSections } from '@/components/market-intelligence';
import { buildReportEnrichmentSchemas } from '@/lib/reportEnrichmentSchemas';
import {
  ReportConsultationBand,
  ReportContentWithAside,
  ReportMidPageCta,
  ReportReadingProgress,
} from '@/components/report-conversion';
import { ReportPremiumHero } from '@/components/report-premium';
import { finalizeStandaloneHealthcareFaqs } from '@/data/standaloneCountryReportContent';

const breadcrumbItems = [
  { name: 'Home', href: '/' },
  { name: 'Turkey Healthcare Market Report', href: '/turkey-healthcare-market-report' },
];

const REPORT_FAQ_ITEMS = finalizeStandaloneHealthcareFaqs([
  {
    question: 'How big is the Turkey healthcare market in 2026?',
    answer: 'The Turkish healthcare market is estimated at USD 45–58 billion in 2026 — the largest in the MENA extended region outside the GCC and Egypt, and among the top 20 globally. Turkey\'s universal healthcare system, the SGK (Sosyal Güvenlik Kurumu, Social Security Institution), covers approximately 98% of the population through its General Health Insurance (GSS) framework. Turkey\'s Health Transformation Program (2003–2013) fundamentally rebuilt the healthcare system — increasing hospital infrastructure, quality metrics, and universal coverage to among the highest levels in the region. Turkey has over 1,500 hospitals, including more than 500 JCI-accredited or internationally recognised private facilities, and is a major medical tourism destination.',
  },
  {
    question: 'What is the Turkey pharmaceutical market size in 2026?',
    answer: 'The Turkish pharmaceutical market is estimated at USD 7–9 billion in 2026. TİTCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu — Turkish Medicines and Medical Devices Agency) is Turkey\'s pharmaceutical and medical device regulator, managing registration, pricing, and surveillance. SGK (Social Security Institution) is the primary payer and manages the SUT (Sağlık Uygulama Tebliği — Health Implementation Circular), which governs reimbursement criteria for all SGK-covered medicines and medical procedures. Turkey operates a reference pricing system with regular price revisions tied to EUR/USD exchange rates — exchange rate volatility significantly impacts pharmaceutical commercial economics. Generic medicine penetration is high; the SGK promotes substitution and has implemented prescribing quota systems (KMD — Kontrollü Miktarda Dağıtım for some specialties).',
  },
  {
    question: 'How does TİTCK drug registration and SGK reimbursement work in Turkey?',
    answer: 'TİTCK registration requires a dossier submission following ICH CTD format. Turkey accepts EMA marketing authorisations as the basis for national registration through a simplified procedure. Following TİTCK registration, manufacturers apply for SGK reimbursement listing in the SUT (Health Implementation Circular). SGK evaluates clinical evidence and cost-effectiveness (HTA is conducted by the HTA Unit within TİTCK). SGK\'s reference pricing system sets the maximum reimbursement price as a percentage of the lowest EU5 reference price — creating a strong international reference pricing linkage. Turkey\'s SGK applies prescribing restrictions, step therapy requirements, and treatment duration limits through the SUT criteria that govern clinical prescribing at SGK-contracted facilities.',
  },
  {
    question: 'What are the largest therapy areas in the Turkey pharmaceutical market?',
    answer: 'The five largest therapy areas in the Turkish pharmaceutical market are: cardiovascular (largest by volume; antihypertensives, statins, anticoagulants at high prescribing rates; Turkey has high cardiovascular disease burden); oncology (fastest-growing by value; Hacettepe University Oncology, Istanbul University cancer institutes, and 200+ private oncology centres expanding biologic and targeted therapy access); immunology and biologics (TNF inhibitors, IL-17/23 inhibitors, JAK inhibitors — SGK has specific reimbursement criteria per biologic class; biosimilar substitution policy aggressively applied); diabetes (insulin analogues, GLP-1 agonists, SGLT-2 inhibitors at high volume; Turkey has high T2DM prevalence); and respiratory (COPD, asthma biologics — SGK reimbursement for dupilumab and mepolizumab within criteria).',
  },
  {
    question: 'Why is Turkey a strategic market at the junction of Europe and the Middle East?',
    answer: 'Turkey\'s unique geopolitical position at the intersection of Europe, the Caucasus, and the Middle East makes it a strategically important market for global pharmaceutical companies managing cross-regional portfolios. Turkey bridges European regulatory frameworks (EMA alignment) with Middle Eastern price expectations and market dynamics. Turkey is the world\'s fourth-largest medical tourism destination — attracting over 1.5 million medical tourists annually, including approximately 300,000 from MENA countries (Saudi Arabia, Libya, Iraq, Azerbaijan). Istanbul\'s position as a regional hub and TİTCK\'s recognition of EMA approvals create operational efficiencies for manufacturers also operating in the EU. Turkey\'s pharmaceutical industry is also a significant exporter — to both European and MENA markets.',
  },
  {
    question: 'How does BioNixus serve Turkey-based pharmaceutical companies expanding to MENA?',
    answer: 'BioNixus supports Turkish pharmaceutical and medical device companies in expanding into GCC and MENA markets. Turkey\'s pharma industry (including major exporters such as Abdi İbrahim, Eczacıbaşı, Zentiva Turkey) has natural market connections to MENA. BioNixus provides SFDA (Saudi Arabia), MOHAP (UAE), and GCC-wide regulatory pathway intelligence; NUPCO tender intelligence; physician panel surveys; and comparative Turkey vs. GCC market intelligence. Turkey\'s medical device and pharmaceutical manufacturers — particularly generic and biosimilar producers — have significant commercial opportunities in GCC markets where BioNixus provides the access intelligence needed.',
  },
], 'turkey');

const REPORT_CONVERSION = getStandaloneReportConfig('/turkey-healthcare-market-report');
const FAQ_SECTION_ID = 'turkey-healthcare-market-faq';

const jsonLd = [
  buildBreadcrumbSchema(breadcrumbItems),
  {
    '@context': 'https://schema.org',
    '@type': 'Article',
    headline: 'Turkey Healthcare Market Report 2026: TİTCK, SGK, and Pharmaceutical Market Intelligence',
    author: { '@type': 'Organization', name: 'BioNixus' },
    publisher: { '@type': 'Organization', name: 'BioNixus', logo: { '@type': 'ImageObject', url: 'https://www.bionixus.com/bionixus-logo.webp' } },
    datePublished: '2026-05-27',
    dateModified: '2026-05-27',
    mainEntityOfPage: 'https://www.bionixus.com/turkey-healthcare-market-report',
  },
  {
    '@context': 'https://schema.org',
    '@type': 'FAQPage',
    url: `https://www.bionixus.com/turkey-healthcare-market-report#${FAQ_SECTION_ID}`,
    mainEntity: REPORT_FAQ_ITEMS.map((item) => ({ '@type': 'Question', name: item.question, acceptedAnswer: { '@type': 'Answer', text: item.answer } })),
  },
  ...buildReportEnrichmentSchemas({
    pageTitle: "Turkey Healthcare Market Report 2026 | TİTCK, SGK Reimbursement & Europe-MENA Crossroads | BioNixus",
    pageMetaDescription: "Turkey healthcare market at USD 50B in 2026. TİTCK drug registration, SGK SUT reimbursement, reference pricing, Health Transformation Program impact, major medical tourism hub, and BioNixus GCC expansion intelligence.",
    countryName: "Turkey",
    marketSlug: "turkey",
    publishedDate: "2026-05-27",
    modifiedDate: "2026-05-27",
  })
];

const TurkeyHealthcareMarketReport = () => (
  <div className="min-h-screen bg-background">
    <Navbar />
    <SEOHead
      title="Turkey Healthcare Market Report 2026 | BioNixus"
      description="Turkey healthcare market at USD 50B in 2026. TİTCK drug registration, SGK SUT reimbursement, reference pricing, Health Transformation Program impact."
      canonical="https://www.bionixus.com/turkey-healthcare-market-report"
      jsonLd={jsonLd}
    />
      <ReportReadingProgress progressId="report-rp-turkey-healthcare-market-report" />
      <main>
      <div className="section-padding pt-24 pb-4"><div className="container-wide"><BreadcrumbNav items={breadcrumbItems} /></div></div>
              <ReportPremiumHero
          title="Turkey Healthcare Market Report 2026: TİTCK, SGK Reimbursement, and Europe-MENA Crossroads Market Intelligence"
          description="BioNixus serves Turkish pharmaceutical and medical device companies with GCC and MENA market intelligence — and provides Turkey market context for global."
          config={REPORT_CONVERSION}
          marketSlug="turkey"
          countryName="Turkey"
          stats={[
            { value: '~$50B', label: 'Turkey healthcare market 2026' },
            { value: '~$8B', label: 'Pharmaceutical market 2026' },
            { value: '~$3.5B', label: 'Medical devices market 2026' },
          ]}
        />
      <ReportContentWithAside config={REPORT_CONVERSION}>
        <section className="section-padding bg-cream-dark" id="executive-summary">
        <div className="container-wide max-w-4xl mx-auto">
          <h2 className="text-2xl md:text-3xl font-display font-semibold text-foreground mb-6">Executive Summary</h2>
          <div className="bg-white rounded-xl border border-border p-6 shadow-sm mb-6">
            <div className="grid sm:grid-cols-3 gap-6 text-center">
              <div><p className="text-3xl font-display font-bold text-primary">~$50B</p><p className="text-xs text-muted-foreground mt-1">Turkey healthcare market 2026</p></div>
              <div><p className="text-3xl font-display font-bold text-primary">~$8B</p><p className="text-xs text-muted-foreground mt-1">Pharmaceutical market 2026</p></div>
              <div><p className="text-3xl font-display font-bold text-primary">~$3.5B</p><p className="text-xs text-muted-foreground mt-1">Medical devices market 2026</p></div>
            </div>
          </div>
          <p className="text-muted-foreground leading-relaxed mb-4">Turkey is the largest healthcare market between Europe and the GCC — a 87-million-population market with near-universal SGK coverage, EMA-aligned regulation, and the world's fourth-largest medical tourism sector. Its position at the Europe-MENA crossroads creates natural strategic relevance for pharmaceutical companies managing multi-regional portfolios.</p>
          <p className="text-muted-foreground leading-relaxed">For GCC/MENA intelligence, see our <Link to="/gcc-pharma-market-report-2026" className="text-primary hover:underline font-medium">GCC Pharmaceutical Market Report 2026</Link>.</p>
        </div>
      </section>
              <MarketIntelligenceSections marketSlug="turkey" countryName="Turkey" variant="healthcare" />

        <section className="section-padding" id="related-intelligence">
          <div className="container-wide max-w-4xl mx-auto">
            <h2 className="text-2xl md:text-3xl font-display font-semibold text-foreground mb-6">Related BioNixus market intelligence</h2>
            <p className="text-muted-foreground leading-relaxed">
              BioNixus runs healthcare and pharmaceutical market research across the wider EMEA region. Benchmark Turkey against our{' '}
              <Link to="/egypt-healthcare-market-report" className="text-primary hover:underline font-medium">Egypt healthcare market report</Link>{' '}and{' '}
              <Link to="/uae-healthcare-market-report" className="text-primary hover:underline font-medium">UAE healthcare market report</Link>, or start from the{' '}
              <Link to="/healthcare-market-research" className="text-primary hover:underline font-medium">global healthcare market research hub</Link>{' '}and our{' '}
              <Link to="/market-research-healthcare" className="text-primary hover:underline font-medium">healthcare market research services</Link>. For therapy-segmented demand and access analysis, see our{' '}
              <Link to="/pharmaceutical-therapy-areas" className="text-primary hover:underline font-medium">pharmaceutical therapy-area coverage</Link>.
            </p>
            <ReportMidPageCta config={REPORT_CONVERSION} className="mt-8" />
          </div>
        </section>

        <FAQSection sectionId={FAQ_SECTION_ID} title="Turkey healthcare market 2026 — TİTCK, SGK, SUT reimbursement, medical tourism, and MENA expansion FAQ" items={REPORT_FAQ_ITEMS} className="bg-muted/30" />        </ReportContentWithAside>
      <ReportConsultationBand config={REPORT_CONVERSION} />
        </main>
    <Footer />
  </div>
);

export default TurkeyHealthcareMarketReport;
